Information regarding the specific price of Velphoro 500mg is not publicly available in the provided context. Pricing for prescription medications can vary significantly based on factors such as insurance coverage, pharmacy, geographic location, and potential patient assistance programs.
How is Velphoro 500mg used?
Velphoro is a chewable tablet containing ferric trichloride hexahydrate. It is used to control serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis [1]. It works by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [1].
When does Velphoro's patent protection end?
Patent expiration dates are crucial for understanding when generic versions of a drug might become available. Information on the specific patent expiry for Velphoro can be found on specialized databases that track drug patents and exclusivity periods. These resources often provide details on the different patents protecting a drug and their respective expiration timelines [2].
Who manufactures Velphoro?
Velphoro is manufactured by Fresenius Medical Care [1].
What are the potential side effects of Velphoro?
The most common side effects reported with Velphoro include diarrhea, nausea, and vomiting [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Velphoro compare to other phosphate binders?
Velphoro belongs to a class of drugs known as phosphate binders. Other phosphate binders include calcium-based binders (like calcium acetate and calcium carbonate), sevelamer (a non-calcium, non-aluminum binder), and lanthanum carbonate [3]. The choice of phosphate binder often depends on individual patient factors, including serum calcium levels, tolerance, and efficacy in controlling phosphorus.
Can I get Velphoro without a prescription?
Velphoro is a prescription medication and requires a prescription from a qualified healthcare provider [1].
What clinical data supports Velphoro's use?
Clinical trials have demonstrated Velphoro's efficacy in reducing serum phosphorus levels in adult patients with CKD on dialysis. Studies have shown a significant reduction in phosphorus levels with Velphoro compared to placebo [1].
Sources:
[1] https://www.velphoro.com/
[2] https://drugpatentwatch.com/
[3] https://www.kidney.org/atoz/content/phosphate-binders